Characterization of a BMS-181174-resistant human bladder cancer cell line

H. Xia, R. J. Bleicher, X. Hu, S. K. Srivastava, V. Gupta, Howard A. Zaren, S. V. Singh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This study was undertaken to elucidate the mechanism of cellular resistance to BMS-181174, a novel analogue of mitomycin C (MMC), in a human bladder cancer cell line. The BMS-181174-resistant variant (J82/BMS) was established by repealed continuous exposures of parental cells (J82) to increasing concentrations of BMS-181174 (9-40 nM) over a period of about 17 months. A 2.6-fold higher concentration of BMS-181174 was required to kill 50% of J82/BMS cell line compared with J82. The J82/BMS cell line exhibited collateral sensitivity to 5-fluorouracil (5-FU), but was significantly more cross-resistant to MMC, melphalan, taxol, doxorubicin and VP-16. NADPH cytochrome P450 reductase and DT-diaphorase activities, which have been implicated in bioreductive activation of MMC, were significantly lower in the J82/BMS cell line than in J82. The cytotoxicity of BMS-181174, however, was not affected in either cell line by pretreatment with dicoumarol, which is an inhibitor of DT-diaphorase activity. These results argue against a role of DT-diaphorase in cellular bioactivation of BMS-181174, a conclusion consistent with that of Rockwell et al. BMS-181174-induced DNA interstrand cross-link (DNA-ISC) frequency was markedly lower in J82/BMS cell line than in J82 at every drug concentration tested. The results of the present study suggest that cellular resistance to BMS-181174 in J82/BMS cell line may be due to reduced DNA-ISC formation. However, the mechanism of relatively lower BMS-181174 induced DNA-ISC formation in J82/BMS cell line than in parental cells remains to be clarified.

Original languageEnglish (US)
Pages (from-to)461-466
Number of pages6
JournalBritish Journal of Cancer
Volume76
Issue number4
DOIs
StatePublished - Jan 1 1997

Fingerprint

Urinary Bladder Neoplasms
Cell Line
NAD(P)H Dehydrogenase (Quinone)
Mitomycin
DNA
Dicumarol
N-7-(2-(nitrophenyldithio)ethyl)mitomycin C
NADPH-Ferrihemoprotein Reductase
Melphalan
Etoposide
Paclitaxel
Fluorouracil
Doxorubicin
Pharmaceutical Preparations

Keywords

  • Bladder cancer
  • Mitomycin C
  • Mitomycin C analogue
  • Resistance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Xia, H., Bleicher, R. J., Hu, X., Srivastava, S. K., Gupta, V., Zaren, H. A., & Singh, S. V. (1997). Characterization of a BMS-181174-resistant human bladder cancer cell line. British Journal of Cancer, 76(4), 461-466. https://doi.org/10.1038/bjc.1997.410

Characterization of a BMS-181174-resistant human bladder cancer cell line. / Xia, H.; Bleicher, R. J.; Hu, X.; Srivastava, S. K.; Gupta, V.; Zaren, Howard A.; Singh, S. V.

In: British Journal of Cancer, Vol. 76, No. 4, 01.01.1997, p. 461-466.

Research output: Contribution to journalArticle

Xia, H, Bleicher, RJ, Hu, X, Srivastava, SK, Gupta, V, Zaren, HA & Singh, SV 1997, 'Characterization of a BMS-181174-resistant human bladder cancer cell line', British Journal of Cancer, vol. 76, no. 4, pp. 461-466. https://doi.org/10.1038/bjc.1997.410
Xia H, Bleicher RJ, Hu X, Srivastava SK, Gupta V, Zaren HA et al. Characterization of a BMS-181174-resistant human bladder cancer cell line. British Journal of Cancer. 1997 Jan 1;76(4):461-466. https://doi.org/10.1038/bjc.1997.410
Xia, H. ; Bleicher, R. J. ; Hu, X. ; Srivastava, S. K. ; Gupta, V. ; Zaren, Howard A. ; Singh, S. V. / Characterization of a BMS-181174-resistant human bladder cancer cell line. In: British Journal of Cancer. 1997 ; Vol. 76, No. 4. pp. 461-466.
@article{51728bb3e4874873a8b34fd9b332c249,
title = "Characterization of a BMS-181174-resistant human bladder cancer cell line",
abstract = "This study was undertaken to elucidate the mechanism of cellular resistance to BMS-181174, a novel analogue of mitomycin C (MMC), in a human bladder cancer cell line. The BMS-181174-resistant variant (J82/BMS) was established by repealed continuous exposures of parental cells (J82) to increasing concentrations of BMS-181174 (9-40 nM) over a period of about 17 months. A 2.6-fold higher concentration of BMS-181174 was required to kill 50{\%} of J82/BMS cell line compared with J82. The J82/BMS cell line exhibited collateral sensitivity to 5-fluorouracil (5-FU), but was significantly more cross-resistant to MMC, melphalan, taxol, doxorubicin and VP-16. NADPH cytochrome P450 reductase and DT-diaphorase activities, which have been implicated in bioreductive activation of MMC, were significantly lower in the J82/BMS cell line than in J82. The cytotoxicity of BMS-181174, however, was not affected in either cell line by pretreatment with dicoumarol, which is an inhibitor of DT-diaphorase activity. These results argue against a role of DT-diaphorase in cellular bioactivation of BMS-181174, a conclusion consistent with that of Rockwell et al. BMS-181174-induced DNA interstrand cross-link (DNA-ISC) frequency was markedly lower in J82/BMS cell line than in J82 at every drug concentration tested. The results of the present study suggest that cellular resistance to BMS-181174 in J82/BMS cell line may be due to reduced DNA-ISC formation. However, the mechanism of relatively lower BMS-181174 induced DNA-ISC formation in J82/BMS cell line than in parental cells remains to be clarified.",
keywords = "Bladder cancer, Mitomycin C, Mitomycin C analogue, Resistance",
author = "H. Xia and Bleicher, {R. J.} and X. Hu and Srivastava, {S. K.} and V. Gupta and Zaren, {Howard A.} and Singh, {S. V.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1038/bjc.1997.410",
language = "English (US)",
volume = "76",
pages = "461--466",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Characterization of a BMS-181174-resistant human bladder cancer cell line

AU - Xia, H.

AU - Bleicher, R. J.

AU - Hu, X.

AU - Srivastava, S. K.

AU - Gupta, V.

AU - Zaren, Howard A.

AU - Singh, S. V.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - This study was undertaken to elucidate the mechanism of cellular resistance to BMS-181174, a novel analogue of mitomycin C (MMC), in a human bladder cancer cell line. The BMS-181174-resistant variant (J82/BMS) was established by repealed continuous exposures of parental cells (J82) to increasing concentrations of BMS-181174 (9-40 nM) over a period of about 17 months. A 2.6-fold higher concentration of BMS-181174 was required to kill 50% of J82/BMS cell line compared with J82. The J82/BMS cell line exhibited collateral sensitivity to 5-fluorouracil (5-FU), but was significantly more cross-resistant to MMC, melphalan, taxol, doxorubicin and VP-16. NADPH cytochrome P450 reductase and DT-diaphorase activities, which have been implicated in bioreductive activation of MMC, were significantly lower in the J82/BMS cell line than in J82. The cytotoxicity of BMS-181174, however, was not affected in either cell line by pretreatment with dicoumarol, which is an inhibitor of DT-diaphorase activity. These results argue against a role of DT-diaphorase in cellular bioactivation of BMS-181174, a conclusion consistent with that of Rockwell et al. BMS-181174-induced DNA interstrand cross-link (DNA-ISC) frequency was markedly lower in J82/BMS cell line than in J82 at every drug concentration tested. The results of the present study suggest that cellular resistance to BMS-181174 in J82/BMS cell line may be due to reduced DNA-ISC formation. However, the mechanism of relatively lower BMS-181174 induced DNA-ISC formation in J82/BMS cell line than in parental cells remains to be clarified.

AB - This study was undertaken to elucidate the mechanism of cellular resistance to BMS-181174, a novel analogue of mitomycin C (MMC), in a human bladder cancer cell line. The BMS-181174-resistant variant (J82/BMS) was established by repealed continuous exposures of parental cells (J82) to increasing concentrations of BMS-181174 (9-40 nM) over a period of about 17 months. A 2.6-fold higher concentration of BMS-181174 was required to kill 50% of J82/BMS cell line compared with J82. The J82/BMS cell line exhibited collateral sensitivity to 5-fluorouracil (5-FU), but was significantly more cross-resistant to MMC, melphalan, taxol, doxorubicin and VP-16. NADPH cytochrome P450 reductase and DT-diaphorase activities, which have been implicated in bioreductive activation of MMC, were significantly lower in the J82/BMS cell line than in J82. The cytotoxicity of BMS-181174, however, was not affected in either cell line by pretreatment with dicoumarol, which is an inhibitor of DT-diaphorase activity. These results argue against a role of DT-diaphorase in cellular bioactivation of BMS-181174, a conclusion consistent with that of Rockwell et al. BMS-181174-induced DNA interstrand cross-link (DNA-ISC) frequency was markedly lower in J82/BMS cell line than in J82 at every drug concentration tested. The results of the present study suggest that cellular resistance to BMS-181174 in J82/BMS cell line may be due to reduced DNA-ISC formation. However, the mechanism of relatively lower BMS-181174 induced DNA-ISC formation in J82/BMS cell line than in parental cells remains to be clarified.

KW - Bladder cancer

KW - Mitomycin C

KW - Mitomycin C analogue

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=0030858759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030858759&partnerID=8YFLogxK

U2 - 10.1038/bjc.1997.410

DO - 10.1038/bjc.1997.410

M3 - Article

C2 - 9275022

AN - SCOPUS:0030858759

VL - 76

SP - 461

EP - 466

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -